Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRX-2 and Pembrolizumab in Advanced Gastric and GEJ Adenocarcinoma
NCT03918499Phase 2Completed
- Sponsor
- City of Hope
- Start
- Apr 2019
- Primary completion
- Feb 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of citoplurikin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by City of Hope. Primary endpoint: Progression-Free Survival at 2 years. Started Apr 2019; status: completed.
02
Drugs
citoplurikin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03918499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03918499.